8/4, 10:58 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Novavax

Novavax's vaccine shows promise in early-stage trial

Novavax's COVID-19 vaccine candidate showed optimistic results in the first-stage human trial, the company said on Tuesday.

The trial included 131 healthy individuals aged 18-59 who were given the vaccine in four different doses. Apart from developing neutralizing antibodies higher than those detected in people who recovered from the coronavirus, the study participants also showed no significant side-effects.

"The Phase 1 data demonstrate that NVX-CoV2373 with our Matrix-M adjuvant is a well‑tolerated COVID-19 vaccine with a robust immunogenicity profile," Gregory Glenn, president for research and development at Novavax, asserted.

Breaking the News / BU